Dr. Mahmud Hassan, Director of Rutgers Business School’s acclaimed Pharmaceutical Management MBA program and of the Blanche and Irwin Lerner Center for Pharmaceutical Management Studies, as well as Professor of Finance and Economics at Rutgers Business School, has been chosen as a Highly Commended Award Winner at the Literati Network Awards for Excellence 2008 for a paper entitled “Do mergers and acquisitions create shareholder wealth in the pharmaceutical industry,” published in International Journal of Pharmaceutical and Healthcare Marketing.
Dr. Hassan, who served as the lead author on the paper, shares the honor with his co-authors Dilip Patro (US Department of Treasury), Howard Tuckman (Fordham University), and former Rutgers Business School PhD student Xiaoli Wang.
Prof. Hassan's paper, the result of a comprehensive study, provides support for the view that in the pharmaceutical industry, acquisitions of US-based companies have a positive impact on wealth creation for shareholders.
Hassan analyzed 405 mergers and acquisitions in the pharmaceutical industry that took place between 1981 through 2004, examining both short- and long-term abnormal returns on investments. The study separated mergers from acquisitions, and US-based from foreign-based target companies. The study showed evidence for the presence of short- and long-term abnormal returns for acquisitions but not for mergers.
Among Dr. Hassan’s areas of expertise are health care economics, health care finance, and health care policy. Since 2000, he has been a professor of Finance and Economics at Rutgers Business School (RBS) as well as director of Rutgers’ MBA in Pharmaceutical Management program. He is the founding director of the Blanche and Irwin Lerner Center for Pharmaceutical Management studies at RBS, established in 2004.
Every year the Emerald Literati Network invites each journal’s editorial team to nominate what they believe has been that title’s Outstanding Paper and up to three Highly Commended Papers from the previous 12 months.
###
About Rutgers Business School-Newark and New Brunswick:
About Rutgers Business School-Newark and New Brunswick is an integral part of one of the nation’s oldest, largest, and most distinguished institutions of higher learning: Rutgers, The State University of New Jersey. Founded in 1929, Rutgers Business School has been accredited since 1941 by AACSB International- the Association to Advance Collegiate Schools of Business — a distinction that represents the hallmark of excellence in management education. Today, Rutgers Business School is educating more than 4,000 undergraduate and graduate students at two main campuses in New Jersey as well as six satellite locations in New Jersey, China, and Singapore. Steeped in academic excellence, with a distinguished faculty and a corps of over 27,000 successful alumni, Rutgers Business School is highly ranked by the Financial Times, U.S. News; World Report, Business Week,and The Wall Street Journal. It is recognized as among the top three business schools in the New York City metropolitan area, and ranked #10 nationwide for “Most Competitive Students” by The Princeton Review. For additional information, visit www.business.rutgers.edu.
Dr. Hassan, who served as the lead author on the paper, shares the honor with his co-authors Dilip Patro (US Department of Treasury), Howard Tuckman (Fordham University), and former Rutgers Business School PhD student Xiaoli Wang.
Prof. Hassan's paper, the result of a comprehensive study, provides support for the view that in the pharmaceutical industry, acquisitions of US-based companies have a positive impact on wealth creation for shareholders.
Hassan analyzed 405 mergers and acquisitions in the pharmaceutical industry that took place between 1981 through 2004, examining both short- and long-term abnormal returns on investments. The study separated mergers from acquisitions, and US-based from foreign-based target companies. The study showed evidence for the presence of short- and long-term abnormal returns for acquisitions but not for mergers.
Among Dr. Hassan’s areas of expertise are health care economics, health care finance, and health care policy. Since 2000, he has been a professor of Finance and Economics at Rutgers Business School (RBS) as well as director of Rutgers’ MBA in Pharmaceutical Management program. He is the founding director of the Blanche and Irwin Lerner Center for Pharmaceutical Management studies at RBS, established in 2004.
Every year the Emerald Literati Network invites each journal’s editorial team to nominate what they believe has been that title’s Outstanding Paper and up to three Highly Commended Papers from the previous 12 months.
###
About Rutgers Business School-Newark and New Brunswick:
About Rutgers Business School-Newark and New Brunswick is an integral part of one of the nation’s oldest, largest, and most distinguished institutions of higher learning: Rutgers, The State University of New Jersey. Founded in 1929, Rutgers Business School has been accredited since 1941 by AACSB International- the Association to Advance Collegiate Schools of Business — a distinction that represents the hallmark of excellence in management education. Today, Rutgers Business School is educating more than 4,000 undergraduate and graduate students at two main campuses in New Jersey as well as six satellite locations in New Jersey, China, and Singapore. Steeped in academic excellence, with a distinguished faculty and a corps of over 27,000 successful alumni, Rutgers Business School is highly ranked by the Financial Times, U.S. News; World Report, Business Week,and The Wall Street Journal. It is recognized as among the top three business schools in the New York City metropolitan area, and ranked #10 nationwide for “Most Competitive Students” by The Princeton Review. For additional information, visit www.business.rutgers.edu.
Media Contact: Bridget Daley
973-353-5177
E-mail: bdaley@business.rutgers.edu